Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Revenue (2017 - 2025)

Historic Revenue for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $54.5 million.

  • Puma Biotechnology's Revenue fell 3236.45% to $54.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.0 million, marking a year-over-year decrease of 1296.31%. This contributed to the annual value of $230.5 million for FY2024, which is 219.36% down from last year.
  • Per Puma Biotechnology's latest filing, its Revenue stood at $54.5 million for Q3 2025, which was down 3236.45% from $52.4 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Revenue ranged from a high of $98.2 million in Q1 2021 and a low of $43.8 million during Q1 2024
  • Over the past 5 years, Puma Biotechnology's median Revenue value was $54.6 million (recorded in 2023), while the average stood at $59.1 million.
  • In the last 5 years, Puma Biotechnology's Revenue soared by 9167.27% in 2021 and then tumbled by 5341.1% in 2022.
  • Puma Biotechnology's Revenue (Quarter) stood at $55.4 million in 2021, then soared by 58.33% to $87.6 million in 2022, then dropped by 17.65% to $72.2 million in 2023, then decreased by 18.15% to $59.1 million in 2024, then fell by 7.79% to $54.5 million in 2025.
  • Its Revenue stands at $54.5 million for Q3 2025, versus $52.4 million for Q2 2025 and $46.0 million for Q1 2025.